Advertisement

Topics

AACR 2018: CheckMate-227 meets co-primary endpoint of PFS in NSCLC

10:56 EDT 16 Apr 2018 | ecancermedicalscience

Among patients with newly diagnosed advanced non-small cell lung cancer (NSCLC) with high tumour mutational burden (TMB, >10 mutations/Mb), those who received nivolumab plus ipilimumab had significantly improved progression-free survival (PFS) compared...

Original Article: AACR 2018: CheckMate-227 meets co-primary endpoint of PFS in NSCLC

NEXT ARTICLE

More From BioPortfolio on "AACR 2018: CheckMate-227 meets co-primary endpoint of PFS in NSCLC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...